FDA Drug Approval and the Ethics of Desperation

被引：16

作者：

Largent, Emily A. ^{[1
]}

Peterson, Andrew ^{[2
]}

Lynch, Holly Fernandez ^{[1
]}

机构：

[1] Univ Penn, Perelman Sch Med, Dept Med Eth & Hlth Policy, 423 Guardian Dr,Room 1403, Philadelphia, PA 19104 USA

[2] George Mason Univ, Dept Philosophy, Inst Philosophy & Publ Policy, Fairfax, VA 22030 USA

来源：

关键词：

D O I：

10.1001/jamainternmed.2021.6045

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：1555 / 1556

页数：2

共 50 条

[11] Drug approval: Future aspects of the FDA
Skelly, JP
METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 1998, 20 (06): : 527 - 537
[12] Overview of FDA Drug Approval and Labeling
Clarridge, Katherine E.
Chin, Stacy J.
Stone, Kelly D.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2022, 10 (12): : 3051 - 3056
[13] FDA to slash drug approval times
不详
CHEMISTRY & INDUSTRY, 2003, (13) : 5 - 5
[14] FDA accelerates drug approval system
Scott, A
CHEMICAL WEEK, 2004, 166 (32) : 42 - 42
[15] FDA shortened drug approval time in 1995
不详
PUBLIC HEALTH REPORTS, 1996, 111 (04) : 290 - 290
[16] 2004 Drug Approval Highlights FDA Update
Laustsen, Gary
Wimmett, Lynn
NURSE PRACTITIONER, 2005, 30 (02): : 14 - 16
[17] FDA drug approval summaries:: Pemetrexed (Alimta®)
Hazarika, M
White, RM
Johnson, JR
Pazdur, R
ONCOLOGIST, 2004, 9 (05): : 482 - 488
[18] FDA drug approval summary:: Panitumumab (Vectibix™)
Giusti, Ruthann M.
Shastri, Kaushikkumar A.
Cohen, Martin H.
Keegan, Patricia
Pazdur, Richard
ONCOLOGIST, 2007, 12 (05): : 577 - 583
[19] RECENT FDA DRUG APPROVAL - TRANEXAMIC ACID
不详
CLINICAL PEDIATRICS, 1987, 26 (12) : 668 - 668
[20] FDA NEW DRUG APPROVAL POLICY - WHY
PATTERSON, R
GRAMMER, LC
NEW ENGLAND AND REGIONAL ALLERGY PROCEEDINGS, 1985, 6 (04): : 379 - 380